CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

21-276

APPROVAL LETTER

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville MD 20857

NDA 21-276

Parke-Davis Pharmaceutical Research
Division of Warner-Lambert
Attention: Joanna Hinton, Ph.D.,
Senior Manager, Worldwide Regulatory Affairs
2800 Plymouth Road
P.O. Box 1047
Ann Arbor, Michigan 48105

Dear Dr. Hinton:

Please refer to your new drug application (NDA) dated June 30, 2000, received July 3, 2000, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for ESTROSTEP® 21 and ESTROSTEP® Fe (norethindrone acetate, 1mg, and ethinyl estradiol, 35mcg) Tablets.

We acknowledge receipt of your submissions dated September 6 and 14, October 9, November 7, 10, and 17, December 20, 2000 (two); January 30, February 22, March 20, April 6, June 26 [(2); one electronic mail], and June 29, 2001[(2)(electronic mail)].

This new drug application provides for the use of ESTROSTEP® 21 and ESTROSTEP® Fe Tablets for the treatment of moderate acne vulgaris in females, ≥15 years of age, who have no known contraindications to oral contraceptive therapy, desire oral contraception, have achieved menarche, and are unresponsive to topical anti-acne medications.

We have completed the review of this application, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the agreed upon enclosed labeling text. Accordingly, the application is approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the package insert, text for the patient package insert, immediate container and carton labels). Marketing the product with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

Please submit the copies of final printed labeling (FPL) electronically according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA* (January 1999). Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved NDA 21-276." Approval of this submission by FDA is not required before the labeling is used.

Be advised that, as of April 1, 1999, all applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred (63 *FR* 66632). We note that you have requested a partial waiver to study ESTROSTEP® 21 and ESTROSTEP® Fe in females <14 years of age for the treatment of moderate acne vulgaris because: (1) moderate acne vulgaris is uncommon in females <14 years, and (2) oral contraceptives are not indicated for women prior to menses due to a possible premature advancement of bone age and its impact on final adult height. The Agency grants you a partial waiver for pediatric acne studies in females <15 years of age, under 21 CFR 314.55(c)(4).

In addition, please submit three copies of the introductory promotional materials that you propose to use for this product. All proposed materials should be submitted in draft or mock-up form, not final print. Please submit one copy to this Division and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-42
Food and Drug Administration
5600 Fishers Lane
Rockville, Maryland 20857

Please submit one market package of the drug product when it is available.

We remind you that you must comply with the requirements set forth under 21 CFR 314.80 and 314.81 for an approved NDA. To comply with these regulations, all 3-day and 15-day alert reports, periodic adverse drug experience reports, field alerts, annual reports, supplements, and other submissions should be addressed to the original NDA for this drug product, not to this NDA. This includes the quarterly periodic adverse drug experience reports required by this new NDA. In the future, no submissions should be made to this NDA except for the final printed labeling, as requested above.

If you have any questions, please call Olga I. Cintron, R.Ph., Project Manager, at (301) 827-2020.

Sincerely,

{See appended electronic signature page}

Jonathan K. Wilkin, M.D.
Director
Division of Dermatologic & Dental Drug Products
Office of Drug Evaluation V
Center for Drug Evaluation and Research

Enclosure